TBK Capital is a boutique merchant banking firm - established to connect private & institutional funders with Business and Property related projects. As a result, we are able to consult on and structure innovative funding options – through traditional sources and via private placement.
The benefit for the borrower is flexibility and choice. The benefit for the funder is the exposure to a multitude of commercial projects – either via debt funding or via equity placement. learn more?
TBK Capital works with businesses to determine their need for funds and the application thereof.
Traditional bank, non-bank and private lending, underwriting and equity and quasi-equity investment including shares, preference shares, convertible notes, and other forms of financial instruments
The aim of this service is to work with clients and to develop strategies around raising equity and debt.
TBK Capital was established to help people to obtain loans, raise money, acquire capital, and partner with others through joint ventures, mergers and acquisitions.
Improving diagnosis of infectious diseases | |
Description: Pictor’s diagnostic products address the need for improved diagnoses of infectious diseases, a global problem brought to everyone’s attention by Covid19. A threat, which by fortune of geography and prompt political and public health actions, New Zealand has managed to keep in check and, in a global sense, effectively avoid. | |
Date: 26/12/2020 | Click here for more information |
New share issue for expansion into China and beyond | |
Description: TBK capital has been involved with the Waiuku-based company DryNZ Ltd for some years now, and has successfully raised capital for the company in the past. It is now seeking working capital to deliver a uniquely New Zealand-harvested and packaged product into the Chinese market; and for intentional expansion. | |
Date: 12/11/2020 | Click here for more information |
Simultaneous testing for multiple diseases | |
Description: Pictor is a New Zealand biotechnology company which has developed a diagnostic platform that can be used for diagnosing multiple diseases, including COVID-19, from a single small blood sample. It will begin clinical trials of this patented diagnostic in USA, Europe and India in January | |
Date: 9/11/2020 | Click here for more information |
Essential Infrastructure Business | |
Description: EPCM Limited is the result of an amalgamation of 4 separate commonly owned New Zealand companies that provide industrial electrical services to blue chip businesses, and government SOEs such as Vector and Transpower. EPCM was deemed an essential business during the Covid-19 lockdown. | |
Date: 21/5/2020 | Click here for more information |
Borrowing and Investment Opportunities | |
Description: Having spent 4 weeks in hospital after a fall, and now already 2 weeks at home under lockdown, I’ve had plenty of time to read, and think, about a wide variety of topics including; | |
Date: 24/4/2020 | Click here for more information |
As an “eventful” calendar year with Covid19 closes, I’ve been looking back over the newsletters sent, and the investment offers we’ve made, over the last 11 months.
1/12/2020 - Read more →
At the moment one could not be criticised for concluding that the New Zealand Capital Markets are failing to accommodate the financial needs of businesses in an open and transparent manner.
26/11/2020 - Read more →
A recent one, as reported in Stuff, says “Here's why things are looking up for the New Zealand economy” which reflects his (and my) opinion that “Our economy is bouncing back, courtesy of good control of the Covid-19 outbreak in New Zealand, high flexibility in our economy, and more”.
9/11/2020 - Read more →
On the 30th October 2017, following the Jacinda Ardern’s election as Prime Minister, I published a newsletter entitled New Government - New Opportunities. In this I said “there appears to be an acceptance from traditional National followers to the change” [in Government].
28/7/2020 - Read more →